Cognitive-behavioral group treatment for disabling headache.

Pain Med

Centers for Behavioral and Preventive Medicine, Brown Medical School and The Miriam Hospital, Lifespan Academic Medical Center, Providence, Rhode Island 02903, USA.

Published: June 2004

Objectives: Severe, disabling headache is costly to individual sufferers, through pain and reduced functioning, and to society, through decreased work productivity and increased health care use. First-line prophylactic agents combined with triptans do not adequately benefit many disabled headache sufferers. We sought to investigate whether a cognitive-behavioral treatment targeting the psychological and behavioral factors that contribute to disabling headache may provide additional benefit and whether using a group format may provide a more intensive clinic-based treatment without increasing the cost of service delivery.

Design: We developed and piloted a cognitive-behavioral group treatment for chronic, disabling headache. We evaluated its effectiveness in decreasing headache, reducing symptomatic medication use, and improving quality of life.

Setting: A behavioral headache management program of an academic medical center.

Patients: Sixty-two individuals suffering from primary headache disorder with moderate to severe headache-related disability who completed treatment.

Interventions: Individuals completed a pretreatment evaluation, the 10-session cognitive-behavioral group treatment, and a 1-month-posttreatment evaluation.

Outcome Measures: The impacts of treatment on headache (frequency, intensity, and duration), medication use, and quality of life were assessed.

Results: Separate multivariate analyses of variance revealed significant improvements in headache, symptomatic medication use, and quality of life. Overall, 50% of participants experienced at least a 50% reduction in headache frequency from pre- to posttreatment.

Conclusions: The findings provide preliminary evidence that delivering a clinic-based, group-format cognitive-behavioral treatment to moderately to severely disabled headache sufferers can decrease headache activity, reduce symptomatic medication use, and improve quality of life.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882886PMC
http://dx.doi.org/10.1111/j.1526-4637.2004.04031.xDOI Listing

Publication Analysis

Top Keywords

disabling headache
16
headache
13
cognitive-behavioral group
12
group treatment
12
symptomatic medication
12
quality life
12
disabled headache
8
headache sufferers
8
cognitive-behavioral treatment
8
headache frequency
8

Similar Publications

Multiple sclerosis (MS) falls within the spectrum of central nervous system (CNS) demyelinating diseases that may lead to permanent neurological disability. Fundamental to the diagnosis and clinical surveillance is magnetic resonance imaging (MRI) that allows for the identification of T2-hyperintensities associated with autoimmune injury that demonstrate distinct spatial distribution patterns. Here, we describe the clinical experience of a 31-year-old, right-handed, White man seen in consultation at The University of Texas Southwestern Medical Center in Dallas, Texas, following complaints of headaches that began after head trauma related to military service.

View Article and Find Full Text PDF

Importance: Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade.

Objective: To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US.

View Article and Find Full Text PDF

Effects of Dietary Interventions in Patients With Migraine: A Systematic Review.

Nutr Rev

January 2025

Dieta, Salud Planetaria y Rendimiento, Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, 28223 Pozuelo de Alarcón, Madrid, Spain.

Context: Migraine is a disabling neurological disorder. Diet may be a factor to consider because measures of diet quality have been linked to both frequency and severity of attacks.

Objectives: To investigate the effects of dietary interventions on the clinical symptoms of migraine, quality of life, and body composition of patients with migraine.

View Article and Find Full Text PDF

Background: Migraine is a disabling disorder that impacts 40 million people in the US. Zavegepant is the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal-spray approved for the acute treatment of migraine with or without aura in adults. This study aimed to evaluate the proportion of patients in various pain and functional disability states over 48-h, for patients treated with zavegepant 10 mg nasal-spray versus placebo.

View Article and Find Full Text PDF

The Dual Burden of Post-Traumatic Headache: Health Consequences and Economic Impact.

Curr Pain Headache Rep

January 2025

Department of Neurology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, USA.

Purpose Of Review: To review the history and impact and burden of post-traumatic headache (PTH).

Recent Findings: PTH is a prevalent headache disorder that many healthcare providers encounter. Unlike more extensively researched primary headache disorders like migraines, PTH has not been as thoroughly studied, and there are fewer treatments specifically tested for it.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!